Recombinant Human CTNNB1 protein, His&GST-tagged

• Cat.No.: CTNNB1-3891H
• Product Overview: Recombinant Human CTNNB1 protein(P35222-1) (Met 1-Leu 781) was expressed in Insect Cells, fused with the N-terminal polyhistidine-tagged GST tag at the N-terminus.

Specification

• Species: Human
• Source: Insect Cells
• Tag: GST&His
• Protein Length: 1-781 aa
• Form: Lyophilized from sterile 50mM Tris, 100mM NaCl, 2mM GSH, 10% gly, pH 8.0.
• Bio-activity: Measured by its ability to bind biotinylated mouse ERBB2 in a functional ELISA.
• Molecular Mass: The recombinant human CTNNB1/GST chimera consists of 1018 amino acids and has a calculated molecular mass of 113 kDa. It migrates as an approximately 116 kDa band in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: > 87 % as determined by SDS-PAGE
• Storage: Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa [ Homo sapiens ]
• Official Symbol: CTNNB1
• Synonyms: CTNNB1; catenin (cadherin-associated protein), beta 1, 88kDa; catenin (cadherin associated protein), beta 1 (88kD), CTNNB; catenin beta-1; beta catenin; CTNNB; FLJ25606; FLJ37923; DKFZp686D02253
• Gene ID: 1499
• mRNA Refseq: NM_001098209
• Protein Refseq: NP_001091679
• MIM: 116806
• UniProt ID: P35222

Case Study

Case 1: Dantzer C, et al. Elife. 2024

β-catenin-mutated tumors resist immunotherapy by disrupting exosome-mediated immune crosstalk. In hepatocellular carcinoma (HCC), oncogenic β-catenin suppresses exosome biogenesis genes SDC4 and RAB27A, reducing exosome secretion (validated via nanoparticle tracking and 3D models), thereby limiting immune infiltration. This study uncovers β-catenin’s role in tumor microenvironment remodeling through exosomal pathway regulation, offering mechanistic insights into immunotherapy resistance. Targeting β-catenin-driven exosome defects could enhance immune checkpoint inhibitor efficacy in HCC.

Fig1. Basal expression of ß-catenin and Rab27a in liver cancer cell lines mutated (HepG2, SNU398, Huh6) or not (Huh7, Hep3B) for ß-catenin.

Fig2. ß-catenin and Rab27a expressions were analyzed by western-blot in Huh7 spheroids treated with DMSO or CHIR99021.

Case 2: Ilhan M, et al. Int J Mol Sci. 2024

Elevated β-catenin in breast cancer links to poor prognosis, yet targeted therapies remain suboptimal. Reduced BMP2/BMP6 expression in tumors correlates with β-catenin accumulation via SMAD4-dependent phosphorylation, lowering its stability and nuclear translocation in MCF7/T47D cells. However, MDA-MB-231/468 cells show no response, suggesting SMAD4 insufficiency. These findings highlight BMP signaling’s role in β-catenin regulation and its potential as a prognostic marker for tumor microenvironment modulation.

Fig1. Endogenous protein expression level of total β-CATENIN, SMAD4, phosphorylated SMAD1/5 and GSK3β (Ser9) in human breast cancer cell line panel.

Fig2. Representative Western blot images and densitometric analysis showing the change in total β-CATENIN protein level.

Application

1. Therapeutic Potential of Recombinant CTNNB1 Protein Recombinant CTNNB1 (β-catenin) protein is increasingly studied for its role in modulating the Wnt/β-catenin signaling pathway, a key driver of cell proliferation and differentiation. In cancer therapeutics, it serves as a tool to investigate β-catenin hyperactivity linked to tumors like colorectal and hepatocellular carcinoma. Preclinical studies suggest that controlled delivery of recombinant CTNNB1 could restore dysregulated signaling in β-catenin-deficient cancers, potentially synergizing with immunotherapy or targeted therapies to suppress tumor growth and metastasis. 2. Applications in Regenerative Medicine and Disease Modeling Beyond oncology, recombinant CTNNB1 aids in stem cell research by promoting tissue regeneration and organoid development. Its integration into 3D disease models helps simulate Wnt pathway dynamics in conditions such as liver fibrosis and neurodegenerative diseases. Additionally, it enables high-throughput drug screening to identify β-catenin pathway modulators, accelerating therapeutic discovery. 3. Diagnostic and Mechanistic Insights As a biomarker, recombinant CTNNB1 facilitates the detection of Wnt pathway aberrations in liquid biopsies, improving early cancer diagnosis. Its use in functional assays clarifies mechanisms of β-catenin nuclear translocation and transcriptional activation, informing strategies to target oncogenic signaling.

Fig1. The extracellular components and signaling transduction of Wnt/β-catenin signaling. (Fanyuan Yu, 2021)